| Literature DB >> 31921168 |
Andreu Garcia-Vilanova1, John Chan2,3, Jordi B Torrelles1.
Abstract
The Mycobacterium tuberculosis cell envelope has been evolving over time to make the bacterium transmissible and adaptable to the human host. In this context, the M. tuberculosis cell envelope contains a peripheral barrier full of lipids, some of them unique, which confer M. tuberculosis with a unique shield against the different host environments that the bacterium will encounter at the different stages of infection. This lipid barrier is mainly composed of glycolipids that can be characterized by three different subsets: trehalose-containing, mannose-containing, and 6-deoxy-pyranose-containing glycolipids. In this review, we explore the roles of these cell envelope glycolipids in M. tuberculosis virulence and pathogenesis, drug resistance, and further, how these glycolipids may dictate the M. tuberculosis cell envelope evolution from ancient to modern strains. Finally, we address how these M. tuberculosis cell envelope glycolipids are impacted by the host lung alveolar environment, their role in vaccination and masking host immunity, and subsequently the impact of these glycolipids in shaping how M. tuberculosis interacts with host cells, manipulating their immune response to favor the establishment of an infection.Entities:
Keywords: Mycobacterium tuberculosis; cell envelope glycolipids; immune responses; immunomodulatory lipids; infectious diseases; tuberculosis; vaccine strategies
Year: 2019 PMID: 31921168 PMCID: PMC6930167 DOI: 10.3389/fimmu.2019.02909
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 7.561
Figure 1The M. tuberculosis complex cell envelope with emphasis on surface glycolipids. The M. tuberculosis cell envelope is composed of a covalently linked core called mycolic-acids-arabinogalactan-peptidoglycan (mAGP) complex. On the top of this core is described to be a peripheral lipid barrier, where lipids intercalate among the mycolic acids of mAGP. Mycolic acids are perpendicular to the plasma membrane. Here the M. tuberculosis cell envelope surface location of mannose-containing glycolipids (phosphatidyl-myo-inositol mannosides, or PIMs) and lipoglycans (e.g., the mannose capped lipoarabinomannan, or ManLAM), as well as trehalose containing lipids [e.g., trehalose-dimycolate (TDM), sulfolipid-1 (SL-1), and diacyl-trehalose (DAT)], is depicted. The trehalose containing lipooligoscharides (LOSs), phthienoates and hydroxyphthienoates, 6-deoxy-pyranose-lipids (phenolic glycolipids, or PGLs), and mannose-containing mannosyl-β-1–phosphomycoketides (MPM) are not depicted. Outer material components (i.e., α-glucan, mannan, arabinomannan, and xylan) are also not shown. Relative number of molecules and size are not accurately depicted, reflecting published experimental data.
Figure 2M. tuberculosis complex mannose-containing lipids mimic mammalian structures allowing the bacterium to gain entry into host cells and thus potentially bypassing the host immune response. M. tuberculosis mannose-containing glycolipids (PIMs) and lipoglycans [ManLAM and lipomannan (LM), and some mannose containing proteins] contain α-2-mannose in their non-reducing termini, mimicking non-siliated mammalian glycoproteins in circulation. These non-siliated mammalian proteins can trigger inflammation, and thus, the host contains a series of homeostatic receptors, such as the mannose receptor (MR), to remove them out from circulation. M. tuberculosis can take advantage of this host clearance system by increasing its mannose surface, allowing the M. tuberculosis bacterium to interact with the homeostatic MR (among others), gaining entry and surviving within host cells. Moreover, these same glycolipids and lipoglycans contain a GPI-anchor of similar structure to mamalian phosphatidyl-inositol, which intercalates within vesicular membranes, regulating vesicular trafficking and fusion.
Figure 3Major glycolipids of the M. tuberculosis cell envelope surface. Three groups of glycolipids can be found on the M. tuberculosis cell envelope: (i) trehalose containing lipids, which involve di-, tri-, and penta-acylated trehaloses (DAT, TAT, PAT); trehalose mono- and di-mycolate (TMM, TDM); sulfolipids (SL-1); and lipooligosaccharides (LOSs); (ii) mannose-containing lipids, which involve the phosphatidyl-myo-inositol mannosides of different lengths (1 to 6 mannoses) and acylation patterns 1 to 4 fatty acid of different nature, being the most common palmitic (16:0) and tuberculostearic acid (TBST); and (iii) 6-deoxy-pyranose containing lipids, mainly phenolic glycolipids (PGLs). LOS and PGL types are restricted to a few strains of the M. tuberculosis complex.
M. tuberculosis cell wall glycolipids and lipoglycans and their interaction with the host.
| Diacyl-, triacyl-, and pentacyl-trehalose (DAT, TAT, and PAT) | ND | Yes | Suppressor (anti-Inflammatory) | Yes | No | Host cell recognition and activation Inhibitor (Mϕ, Nϕ, AT) Phagocytosis inhibitor B-cell priming T-cell proliferation inhibitor | Initial infection establishment Increase transmissibility |
| Trehalose dimycolate (TDM) | Mincle-FcγR TLRs | Yes | Stimulator (pro-inflammatory) | Yes | Yes | Host cell recognition and activation (Mϕ, Nϕ, AT) Inflammasome activation Apoptosis | Initial infection establishment Granuloma formation and maintenance Cavitation Increase transmissibility |
| Trehalose monomycolate (TMM) | ND | ND | Stimulator (pro-inflammatory) | Yes | Yes | Apoptosis | Initial infection establishment Granuloma formationand maintenance Cavitation Increase transmissibility |
| Lipooligosaccharides (LOSs) | ND | ND | Suppressor (anti-inflammatory) | Yes | ND | Host cell recognition (Mϕ, others?) Motility | Initial infection Decrease transmissibility |
| Sulfated trehalose glycolipid family(SL-1, Ac2SGL) | ND | Yes | Suppressor (anti-inflammatory) | Yes | Yes (Ac2SGL only) | Host cell recognition and activation Inhibitor (Mϕ, DCs, others?) Phagocytosis inhibitor Inflammasome inhibition T-cell proliferation activator | Initial infectionestablishment Increase transmissibility |
| Phenolic glycolipid(PGL-TB) | CR3? | ND | Anti-/Pro-Inflammatory | Yes | Yes | Host cell recognition and activation (Mϕ, others?) | Initial infection Granuloma formation and maintenance (chronic infection) |
| Phthiocerol dimycocerosate (PDIM) | Direct insertion into host Mbrs | Yes | Suppressor (anti-inflammatory) | Unknown | Yes | Host cell recognition and activation (Mϕ, DCs, others?) | Initial infection Cavitation Increase transmissibility |
| Lower-order phosphatidyl- | CR3, TLRs, DC-SIGN | No | Stimulator (pro-inflammatory) | Yes | ND | Host cell recognition and activation (Mϕ, Nϕ, others?) Early endosome fusion stimulator Oxidative response stimulator Activate T-cell proliferation via CD1 | Initial infection establishment |
| Higher-order phosphatidyl- | MR, DC-SIGN | Yes (through the MR only) | Suppressor (anti-inflammatory) | Yes | ND | Host cell recognition and activation (Mϕ, Nϕ, others?) Apoptosis modulator Activate T-cell proliferationvia CD1 | Initial infection establishment Granuloma formation and maintenance (chronic infection) |
| Lipomannan (LM) | TLRs, | No | Stimulator (pro-inflammatory) | Yes | ND | Host cell recognition and activation (Mϕ, Nϕ, others?) Apoptosis modulator Activate T-cell proliferationvia CD1 | Initial infection establishment |
| Mannose-capped lipoarabinomannan (ManLAM) | MR, | Yes (through the MR only) | Suppressor (anti-inflammatory) | Yes | ND | Host cell recognition and activation (Mϕ, Nϕ, others?) Apoptosis modulator Activate T-cell proliferationvia CD1 | Initial infectionestablishment Granuloma formation and maintenance (chronic infection) |
Figure 4Hypothetical distribution of glycolipids on the M. tuberculosis bacterium cell envelope surface at the different stages of infection. The transmissible bacterium is thought to contain a large number of glycolipids (DAT, TAT, PAT, SL-1, TMM, TDM, PDIMS, PIMs, etc.) on the cell envelope driving surface hydrophobicity, which in turn favors its transmission through the air. Upon infection and after reaching the alveolar space, M. tuberculosis gets in contact with alveolar lining fluid (ALF; hypophase of the lung mucosa). ALF contains an array of homeostatic hydrolases that significantly alter the M. tuberculosis cell envelope surface removing glycolipids and lipoglycans, and thus somehow altering its cell surface hydrophobicity and determining how the bacterium will interact with alveolar host cells. After phagocytosis by AMs, the bacterium is shown to hyperproduce PIMs, as well as switching to metabolic networks such as beta-oxidation, glyoxylate shunt, and the reverse methylcitrate cycle. This metabolic switch within host cells allows the bacterium to break down own and host captured long-chain fatty acids and cholesterol to generate acetyl-CoA and propionyl-CoA, increasing its production of mycolic acids in detriment of producing glycolipids. This bacterium metabolic state is thought to be maintained at latency stages when the bacterium remains intracellular within granulomas. Upon reactivation, the bacterium metabolic state changes again increasing glycolipid production in detriment of producing mycolic acids, restoring the bacterium surface hydrophobicity, while remaining extracellular within granulomas. This bacterial surface hydrophobicity gets further accentuated when M. tuberculosis escapes disrupted granulomas becoming extracellular within cavities, where host-driven hydrolytic destruction of tissues enhances M. tuberculosis escape to the blood stream and airways becoming transmissible again closing the cycle. Relative number of molecules and size are not accurately depicted reflecting published experimental data.